Reading Open Targets: evidence connecting diseases and targets

Reading disease–target connections in Open Targets: Nadoo Bio public database series

The Open Targets Platform is a public platform that brings together research evidence supporting relationships between genes or proteins and diseases. In drug discovery, a target is a biological entity whose activity researchers aim to change with a drug; proteins are a common example. Open Targets helps identify disease-related targets and explore which ones warrant further research. [1]

A single disease can have many associated targets. Some studies investigate genetic differences; others examine tissue changes or drug responses. Open Targets organizes these scattered findings around target–disease relationships. From a target list, you can follow a relationship back to the studies that support it.

Finding targets associated with a disease

Open Targets organizes target information around genes. When studying an actual protein, the next step is to connect the gene to information about that protein's sequence and function.

A gene is a stretch of DNA containing information for producing a protein or functional RNA. RNA is a molecule that carries genetic information or performs functions within a cell. Some genes do not produce proteins, so the platform's gene information must be connected to the particular protein under investigation.

An association in Open Targets collects evidence supporting a relationship between a target and a disease. Studies from different sources can connect to the same target–disease pair. [2] The individual evidence records reveal what was actually observed.

Genetic, expression, and drug evidence connect a disease and a target

Different kinds of research can examine the same disease–target relationship.

What three kinds of evidence tell us

Genetic evidence includes relationships between genetic differences and disease. It considers which differences occur with a disease and how those differences were linked to a particular target. This can point to biological processes involved in disease.

Expression evidence describes how much of a gene's products—RNA or protein—appears in a tissue or under particular conditions. A change in diseased tissue helps identify what has changed. Whether that change caused the disease or resulted from it is a question for further research.

Drug evidence describes relationships between drugs, targets, and diseases. It includes both approved treatments and drugs still in development, so interpretation depends on the development stage represented. [3]

When different kinds of studies support the same relationship, there is more evidence to consider. However, the number of records is not necessarily the number of independent studies. Following the sources helps determine whether several records originate from the same research.

How to read association scores

Association scores combine evidence across sources, taking account of weights assigned to data types and sources. They can help narrow a long target list for closer examination. [2]

A score of 0.8 does not mean an 80% chance of treatment success. The score summarizes the collected association evidence. Establishing a particular drug's safety and effectiveness requires separate research. A low score can also reflect limited data or differences in coverage.

Read the scope of the disease alongside the score. Specific diseases are linked to broader parent categories. A display may include direct evidence for the disease being examined and indirect evidence propagated from more specific diseases to a broader category. Knowing which disease a study actually investigated helps assess its relevance to your question. [2]

Reviewing an association score, reading the evidence, and choosing the next research question

Scores narrow the search; individual evidence records explain why a relationship merits further study.

Questions that follow an association

Suppose evidence links a disease to protein A. Drug development still requires more specific answers: should A's activity be reduced or increased, in which tissue should it be changed, and how would normal functions elsewhere be affected?

These questions require functional studies, experiments, and evidence about whether a drug can modulate the target. Even a target closely associated with a disease may be difficult to alter in the desired direction. Finding an association and finding a way to intervene with a drug are connected stages of investigation.

The original sources behind each evidence record describe what was studied and observed. This is where a search that began with a score reaches the substance of the research.

The questions addressed by six databases

Open Targets provides a way to survey disease–target relationships broadly and then examine individual studies. Its strength lies in showing which relationships different evidence supports, rather than selecting a candidate from a single score.

The six databases in this series answer different questions. UniProt covers protein identity and sequence; PDB provides experimentally determined shapes; AlphaFold DB offers AI-predicted shapes. PubChem connects compound structures with their sources, ChEMBL connects measurements with assay conditions, and Open Targets connects diseases with target evidence. Following a question from one resource to another makes each database's role clearer.

Terms of use

Data distributed by the Open Targets Platform may be used for research and commercial purposes. Its CC0 dedication waives copyright and related rights to the extent permitted by law so that anyone can reuse the material. Copying, modification, and redistribution do not require separate permission, and CC0 itself does not make attribution a condition of reuse. [4] [5]

Open Targets asks researchers using its data to cite the platform's relevant publications. If you separately obtain data from an original database or the full text of a paper, that material's own terms apply. Other rights, such as patents and trademarks, are distinct from CC0. [4] [5]

References

  1. Open Targets. Open Targets Platform. Official documentation. Checked October 23, 2026.

  2. Open Targets. Target–disease associations. Official documentation. Checked October 23, 2026.

  3. Open Targets. Target–disease evidence. Official documentation. Checked October 23, 2026.

  4. Open Targets. Licence. Usage policy. Checked October 23, 2026.

  5. Creative Commons. CC0 1.0 Universal. Public domain dedication summary. Checked October 23, 2026.